A Concise Look at the IMMPulse Trial Comparing Apremilast And Risankizumab In Moderate Plaque Psoriasis
In a compelling video interview for the Journal of Drugs in Dermatology, Dr. Christopher Bunick delves into the evolving landscape of moderate-to-severe plaque psoriasis, with a special emphasis on the IMMPulse Head-to-Head Study. As a leading expert in dermatologic therapeutics, he shares how molecular insights into PDE4 inhibition set the stage for a rigorous comparison of apremilast and the IL-23 inhibitor risankizumab.
Dr. Bunick underscores the pivotal role that the IMMPulse trial plays in clarifying where apremilast fits in today’s treatment armamentarium. By adopting precise criteria to define moderate disease—encompassing body surface area involvement, patient-reported severity, and functional impact—the study delivers clarity for clinicians who must tailor therapies based on nuanced patient presentations.
Dr. Bunick touches on safety, patient satisfaction, and quality-of-life outcomes, and considers whether IL-23 inhibition might deserve a place earlier in therapy. His one key takeaway: IMMPulse challenges traditional sequencing and underscores the impact of selecting the right mechanism up front.
If you’ve watched the video below and want to read more? Discover the article “PDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact” from the June 2025 JDD issue here.
